BSGM BioSig Technologies Inc.

3.08
0  0%
Previous Close 3.08
Open 3.04
52 Week Low 2.26
52 Week High 6.14
Market Cap $108,756,731
Shares 35,310,627
Float 30,997,949
Enterprise Value $92,026,731
Volume 109,250
Av. Daily Volume 242,468
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
Merimepodib and remdesivir
COVID-19
Phase 2
Phase 2
Phase 2 trial halted - October 26, 2020. Unlikely that the trial would meet its primary safety endpoints.

Latest News

  1. Westport, CT, Nov. 17, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would participate in The Benchmark Company 10th Annual Discovery One on One Investor Conference (Virtual) on Thursday, December 2, 2021.

    The Company's executive leadership will provide a business update on the roll-out of its FDA 510(k) cleared medical device, the PURE EP™ System, that aims to drive procedural efficiency and efficacy in cardiac electrophysiology and outline key priorities for the next phase of its commercial…

    Westport, CT, Nov. 17, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would participate in The Benchmark Company 10th Annual Discovery One on One Investor Conference (Virtual) on Thursday, December 2, 2021.

    The Company's executive leadership will provide a business update on the roll-out of its FDA 510(k) cleared medical device, the PURE EP™ System, that aims to drive procedural efficiency and efficacy in cardiac electrophysiology and outline key priorities for the next phase of its commercial and clinical growth. To date, 73 physicians have completed over 1700 patient cases with the PURE EP™ System. The Company is in a focused commercial launch of the PURE EP™ System in the Northeast, Texas, and Florida. The technology is regularly used in some of the country's highest-ranked hospitals, including St. David's Medical Center in Austin, TX, Mayo Clinic campuses in Florida, Minnesota, and Arizona, and University of Pennsylvania in Philadelphia, PA. The Company recently completed its first clinical trial and is hosting a roundtable to discuss the results. The event, led by the three industry experts, will be held on November 18, 2021, at 8 pm ET.

    The Benchmark Company 10th Annual Discovery One on One Investor Conference

    Date: Thursday, December 2nd, 2021

    Time: 8 am – 4 pm EST

    For parties interested in scheduling a one-on-one meeting with BioSig management, please contact the conference coordinators at:

    About The Benchmark Company Discovery Conference

    The Annual Benchmark Company Discovery Conference is hosted by The Benchmark Company, a boutique investment banking firm headquartered in New York, with regional offices across the country. Benchmark provides Research, Sales, Trading, and Investment Banking services to public and private companies, institutional and high net worth investors, and family offices. The conference is regularly attended by more than 150 institutional investors and will feature approximately 50 presenting companies.

    About BioSig Technologies

    BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

    The Company's first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

    Forward-looking Statements

    This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.



    Andrew Ballou
    BioSig Technologies, Inc. 
    Vice President, Investor Relations 
    55 Greens Farms Road
    Westport, CT 06880
    
    203-409-5444, x133
    
    

    Primary Logo

    View Full Article Hide Full Article
  2. Westport, CT, Nov. 16, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company entered into a feasibility study with The Technion Research & Development Foundation Ltd.

    Based in Haifa, Israel, Technion – Israel Institute of Technology is a public research university offering degrees in science, engineering, and related fields, such as medicine, industrial management, and education. Over the years, the Technion established itself as a leading academic institution in Artificial…

    Westport, CT, Nov. 16, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company entered into a feasibility study with The Technion Research & Development Foundation Ltd.

    Based in Haifa, Israel, Technion – Israel Institute of Technology is a public research university offering degrees in science, engineering, and related fields, such as medicine, industrial management, and education. Over the years, the Technion established itself as a leading academic institution in Artificial Intelligence (AI). It is currently ranked as number one in AI in Europe and 15th in the world, with 100 faculty members engaged in areas across the AI spectrum.

    The feasibility program with BioSig will be led by Asst. Prof. Joachim Behar, Head of the Artificial Intelligence in Medicine Laboratory (AIMLab) at the Technion. Under the terms of the program, the ECG signals supplied by the PURE EP(tm) System, the Company's signal processing technology for arrhythmia care, will be analyzed in the context of developing AI-powered algorithms for atrial fibrillation ablation procedures.

    "Artificial Intelligence is promptly becoming an essential tool for increasing efficiency and driving value in many sectors of healthcare, but predictive insights that form the foundation for machine learning solutions are dependant on the high-quality input data. Our clinical work provides us with vast volumes of smaller, often undetectable cardiac signals that hold additional diagnostic information, and we are thrilled to partner with Prof. Behar and his Technion team to take our AI work to the next level. Their expertise in developing deep learning systems for ECG records is invaluable to this program, and we look forward to reporting on the progress of this promising new project," commented Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc.

    "The laboratory for artificial intelligence in medicine (AIMLab.) at the Technion focuses on the usage of advanced signal processing and machine learning in medicine within the context of physiological time series analysis with a specific focus in cardiology where we have 10 years of expertise in processing and analysing the ECG signal. In particular, in our most recent research we have developed robust deep learning algorithms for AF diagnosis and risk prediction working on large databases - totalling over a million ECG recordings. We look forward to contributing our expertise to support leading industry in the field providing novel clinical ECG analysis tools. Our new partnership with BioSig is aligned with this desire to contribute and impact the medical field through AI powered algorithms to support clinical decision making in cardiology," commented Asst. Prof. Behar.

    One in 18 Americans suffers from a cardiac arrhythmia. Atrial fibrillation is the most common arrhythmia type, affecting over 33 million people worldwide, including over 6 million in the U.S. The number of people suffering from atrial fibrillation is expected to reach 8-12 million by 20501. According to the Centers for Disease Control and Prevention (CDC), atrial fibrillation causes more than 750,000 hospitalizations in the U.S. each year, resulting in approximately $6 billion in healthcare spending annually2.

    The PURE EP(tm) is an FDA 510(k) cleared non-invasive class II device that aims to drive procedural efficiency and efficacy in cardiac electrophysiology. To date, over 70 physicians have completed over 1600 patient cases with the PURE EP(tm) System. Clinical data acquired by the PURE EP(tm) System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David's Medical Center, Mayo Clinic Jacksonville and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library. Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP(tm) signals over conventional sources.

    About Technion – Israel Institute of Technology

    Founded in 1912, Technion-Israel Institute of Technology is Israel's first university and its largest center of applied research. Technion is ranked among the leading technological universities worldwide.  A major source of the innovation and brainpower that drives the Israeli economy, Technion is the engine behind Israel's renown as the iconic "Startup Nation." Technion people, ideas, and inventions have made, and continue to make tremendous scientific contributions in fields such as medicine, sustainable energy, computer science, water conservation, and nanotechnology. It is one of a handful of technological institutes worldwide with a medical school, facilitating the rapid development of advanced therapies and devices, from the laboratory to the patient's bedside.

    Technion's success is attributed to its unwavering commitment to excellence in education and research. The University is proud of its four Nobel laureates – Aaron Ciechanover, Avram Hershko, Dan Shechtman, and Arieh Warshel. Technion currently ties with MIT in 8th place for the number of Nobel prizewinners this century.

    In 2011, Technion and Cornell University partnered to establish an applied science and engineering institution in New York City: The Joan and Irwin Jacobs Technion Cornell Institute (JTCI). In 2013, Technion joined with Shantou University to establish the Guangdong Technion-Israel Institute of Technology (GTIT) in China.

    The Technion Research and Development Foundation (TRDF) manages university research programs and performs testing and research services for industry and government. T3, the technology transfer arm of TRDF, takes the university's game-breaking scientific ideas and matches them with investors and entrepreneurs, licensing intellectual property and supporting the establishment of startup companies.



    About BioSig Technologies

    BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

    The Company's first product, PURE EP (tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

    Forward-looking Statements

    This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. 






    1 Top 10 Things You should Know About Heart Rhythm; Scripps Health.

    2 Managing Atrial Fibrillation; Lisa Eramom MA, Medical Economics Journal, February 25, 2019, Volume 96, Issue 4





    Andrew Ballou
    BioSig Technologies, Inc. 
    Vice President, Investor Relations 
    55 Greens Farms Road
    Westport, CT 06880
    
    203-409-5444, x133
    
    

    Primary Logo

    View Full Article Hide Full Article
  3. Westport, CT, Nov. 11, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced
    that it will host a live roundtable webinar to discuss the PURE EP 2.0 study results recently published in the Journal of Cardiovascular Electrophysiology. The live webinar, titled, "PURE EP 2.0 Study Results: From Clinical Data to Clinical Applications," will air on Thursday, November 18, 2021, from 8pm -9pm EST.

    The roundtable will be led by three industry experts: Andrea Natale, M.D., Executive Medical Director, and Amin Al-Ahmad…

    Westport, CT, Nov. 11, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced

    that it will host a live roundtable webinar to discuss the PURE EP 2.0 study results recently published in the Journal of Cardiovascular Electrophysiology. The live webinar, titled, "PURE EP 2.0 Study Results: From Clinical Data to Clinical Applications," will air on Thursday, November 18, 2021, from 8pm -9pm EST.

    The roundtable will be led by three industry experts: Andrea Natale, M.D., Executive Medical Director, and Amin Al-Ahmad, M.D., Cardiac Electrophysiologist at St. David's Medical Center in Austin TX; and Wendy Tzou, MD., Director of Electrophysiology at the University of Colorado in Denver. The faculty panel will review the recently published study results and discuss the integration of high-fidelity signals into the current procedural workflow and the impact of advanced signal processing technology on cardiac ablation procedures and beyond.

    To register for the event, please click here.

    Webinar Details:

    Date: Thursday, November 18, 2021

    Time: 8 pm – 9 pm (ET)

    Clinical data acquired by the PURE EP™ System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David's Medical Center, Mayo Clinic Jacksonville and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library. Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP(tm) signals over conventional sources.

    About BioSig Technologies

    BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

    The Company's first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

    Forward-looking Statements

    This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.





    Andrew Ballou
    BioSig Technologies, Inc. 
    Vice President, Investor Relations 
    55 Greens Farms Road
    Westport, CT 06880
    
    203-409-5444, x133
    
    

    Primary Logo

    View Full Article Hide Full Article
  4. Westport, CT, Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it is installing a PURE EP™ System for an evaluation at the HCA Healthcare-operated Medical City Heart Hospital in Dallas, TX. This is the Company's 17th installation and its fifth in Texas, the state with some of the most extensive clinical programs focused on arrhythmia care in the country.

    Opened in 2019, Medical City Heart Hospital, a cardiovascular department of Medical City Dallas Hospital, provides the most comprehensive…

    Westport, CT, Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it is installing a PURE EP™ System for an evaluation at the HCA Healthcare-operated Medical City Heart Hospital in Dallas, TX. This is the Company's 17th installation and its fifth in Texas, the state with some of the most extensive clinical programs focused on arrhythmia care in the country.

    Opened in 2019, Medical City Heart Hospital, a cardiovascular department of Medical City Dallas Hospital, provides the most comprehensive heart and vascular treatment in the Southwest. As a part of Medical City Healthcare, the facility offers highly specialized advanced cardiovascular care, including leading-edge treatments and technology, ground-breaking clinical trials, and seamless access to the entire network of Medical City Healthcare hospitals and specialists. 

    "Heart disease and stroke remain at the top of leading causes of disability in Texas1, and we are committed to working with more physicians in this state as they strive to reduce the societal burden caused by heart disease. Medical City Heart provides specialized care for all types of cardiac rhythm disorders, and we are looking forward to contributing our technological and clinical know-how in this new collaboration," commented Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc.

    To date, over 71 physicians have completed over 1600 patient cases with the PURE EP™ System. The Company is in a focused commercial launch of the PURE EP™ System in the Northeast, Texas, and Florida. The technology is regularly used in some of Texas's highest-ranked hospitals, including St. David's Medical Center, Houston Methodist Hospital, and Medical City North Hills.

    Clinical data acquired by the PURE EP™ System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David's Medical Center, Mayo Clinic Jacksonville and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library. Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP™ signals over conventional sources.

    About 2,300 Americans die from heart disease each day – an average of one death every 38 seconds2. In 2016, 1.6 million Texas adults reported that they had been diagnosed with heart disease or stroke3. There were 336,462 hospitalizations of adult Texans related to heart disease in 2016, at an age-adjusted rate of 124.0 per 10,000 adults4. The direct and indirect costs of heart disease and stroke in the U.S. are estimated to be $329.7 billion, and the cost is projected to increase to $749 billion by 20355.

    About BioSig Technologies

    BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

    The Company's first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

    Forward-looking Statements

    This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.






    1 Prevalence of Heart Disease Among Adults, by Demographic Characteristics, Risk Factors / Comorbid Conditions, and Place of Residence, Texas 2018; Chronic Disease Epidemiology Branch, Texas Department of State Health Services.

    2 Heart disease and stroke statistics – 2018 update: a report from the American Heart Association

    3 Texas Behavioral Risk Factor Surveillance System Public Use Data File, 2016, Center for Health Statistics, Texas Department of State Health Services

    4 Texas Hospital Inpatient Discharge Public Use Data, Texas Health Care Information Collection, 2016, Center for Health Statistics, Texas Department of State Health Services

    5 Heart disease and stroke statistics – 2018 update: a report from the American Heart Association







    Andrew Ballou
    BioSig Technologies, Inc. 
    Vice President, Investor Relations 
    55 Greens Farms Road
    Westport, CT 06880
    
    203-409-5444, x133
    
    

    Primary Logo

    View Full Article Hide Full Article
  5. Westport, CT, Nov. 08, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it is installing a PURE EP™ System for an evaluation at the Beth Israel Deaconess Medical Center (BIDMC) in Boston, MA. This new evaluation agreement brings the Company up to 16 installed centers. Procedural cases are expected to commence in early December at this renowned medical center.

    Beth Israel Deaconess Medical Center is a world-class teaching hospital of Harvard Medical School. It is part of Beth Israel Lahey Health…

    Westport, CT, Nov. 08, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it is installing a PURE EP™ System for an evaluation at the Beth Israel Deaconess Medical Center (BIDMC) in Boston, MA. This new evaluation agreement brings the Company up to 16 installed centers. Procedural cases are expected to commence in early December at this renowned medical center.

    Beth Israel Deaconess Medical Center is a world-class teaching hospital of Harvard Medical School. It is part of Beth Israel Lahey Health, a new healthcare system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, and more than 4,000 physicians, and 35,000 employees.



    "Harvard's scientific and clinical legacy in cardiology is appreciated worldwide.  Drs. Mark Josephson and Dr. Peter Zimetbaum provided the original inspiration for launching this technology and it is exciting to be able to bring our platform to this original site of conception. It is a true privilege to be able to work with some of the best clinician-educators at Beth Israel and Harvard Medical School, and we have no doubt that this clinical collaboration will lead to impactful results both for our clinical and commercial strategies and for the broader field," commented Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc.

    To date, over 71 physicians have completed over 1600 patient cases with the PURE EP™ System. The Company is in a focused commercial launch of the PURE EP™ System in the Northeast, Texas, and Florida. The technology is in regular use in some of the country's leading centers of excellence, including Mayo Clinic, Texas Cardiac Arrhythmia Institute at St. David's Medical Center, and New York Presbyterian / Weill Cornell Medical Center.

    Clinical data acquired by the PURE EP™ System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David's Medical Center, Mayo Clinic Jacksonville and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library. Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP™ signals over conventional sources.

    One in 18 Americans suffers from a cardiac arrhythmia. Atrial fibrillation is the most common arrhythmia type, affecting over 33 million people worldwide, including over 6 million in the U.S. The number of people suffering from atrial fibrillation is expected to reach 8-12 million by 20501. According to the Centers for Disease Control and Prevention (CDC), atrial fibrillation causes more than 750,000 hospitalizations in the U.S. each year, resulting in approximately $6 billion in healthcare spending annually2.

    About BioSig Technologies

    BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

    The Company's first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

    Forward-looking Statements

    This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.






    1 Top 10 Things You should Know About Heart Rhythm; Scripps Health.

    2 Managing Atrial Fibrillation; Lisa Eramom MA, Medical Economics Journal, February 25, 2019, Volume 96, Issue 4





    Andrew Ballou
    BioSig Technologies, Inc. 
    Vice President, Investor Relations 
    55 Greens Farms Road
    Westport, CT 06880
    
    203-409-5444, x133
    
    

    Primary Logo

    View Full Article Hide Full Article
View All BioSig Technologies Inc. News